Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jan 16, 2019 4:33pm

125 Views

Post# 29242044

RE:RE:from Bear = 2019 Potential Events

An example for a drug/trial that you may have heard of before was presented as an LBCT at last year's ACC. ODYSSEY trial for alirocumab PCSK9 inhibitor No top-line data reveal prior to full data set being revealed and presented at March 10, 2018 ACC meeting. https://mediaroom.sanofi.com/en/press-releases/2018/praluent-alirocumab-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients/

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale